Primary resistance of Helicobacter pylori
Abstract
Background: Antimicrobial resistance, particularly against metronidazole and clarithromycin, is the leading cause for treatment failure of Helicobacter pylori infection. Eradication rates of primary therapy have fallen below 80% in the majority of states including Slovenia. h e aim of the study was to assess primary resistance to key antibiotics used for eradication treatment. Patients and methods: Between 2007 and 2009 we isolated 97 strains of Helicobacter pylori from the treatment naive patients who have not previously underwent eradication treatment. Antimicrobial susceptibility testing was done using phenotypical methods, Etests and breakpoint agar dilution method for metronidazole. We analyzed resistance proi les of the isolated bacteria and presented distribution of dif erent phenotypes of Helicobacter pylori. Results: h e primary antimicrobial resistance for metronidazole and clarithromycin was 18.6% and 17.5%, respectively. Combined resistance for both metronidazole and clarithromycin was 4.1%. In our group of isolates we did not i nd any resistance against amoxicillin and tetracycline. 3.1% of isolates were ciprol oxacin resistant. Conclusions: Systematic surveillance of antimicrobial resistance of Helicobacter pylori is mandatory to adjust primary and subsequent eradication therapy. Performing antimicrobial susceptibility testing is a costly method and that is why it is important to i nd resources to make it possible.
Downloads
References
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
